Encyclopedia of contested claims
Mammography screening is associated with lower breast cancer mortality in many studies, but estimates vary by age group, screening schedule, baseline risk, and how harms such as overdiagnosis are counted. The overall assessment is likely mixed because population-level benefit coexists with meaningful uncertainty and tradeoffs.
7 reviewing models concluded the claim is not supported by the available evidence.
The Adjudged panel has not yet completed its review of this claim. This draft summarizes the main questions, likely evidence streams, and points of uncertainty for later expert assessment; it should not be read as a final adjudication.
Mammography screening is associated with lower breast cancer mortality in many studies, but estimates vary by age group, screening schedule, baseline risk, and how harms such as overdiagnosis are counted. The overall assessment is likely mixed because population-level benefit coexists with meaningful uncertainty and tradeoffs.
The claim asks whether screening mammography reduces deaths from breast cancer among people without symptoms. It is not asking whether mammography can detect breast cancer, which is broadly accepted, but whether routine screening changes mortality outcomes enough to justify population-level recommendations.
A precise judgment needs to specify the population being screened. Evidence and recommendations often differ for women ages 40 to 49, 50 to 74, and 75 or older, and may differ for people at elevated genetic or family-history risk. Screening intervals, such as annual versus biennial mammography, also affect the balance of benefit and harm.
The central outcome is breast cancer-specific mortality, not overall mortality. Some studies report reductions in deaths attributed to breast cancer, while effects on all-cause mortality are harder to detect because breast cancer deaths are a small fraction of total deaths in screened populations.
Randomized trials and long-term observational studies generally suggest that mammography screening can reduce breast cancer mortality, especially among women in age ranges where breast cancer incidence is higher. However, the size of the estimated reduction varies across trials, eras, and analytic methods.
The benefit appears more consistent for women roughly ages 50 to 74 than for women in their 40s. In younger women, lower baseline incidence, denser breast tissue, and higher false-positive rates can reduce the net population benefit, although some individuals may still benefit.
Modern treatment improvements complicate interpretation. As breast cancer therapy has improved, the incremental mortality reduction attributable to earlier detection through screening may differ from estimates produced in earlier trial eras.
Potential harms are part of the evidence base. Screening can lead to false-positive results, additional imaging or biopsies, anxiety, radiation exposure, and overdiagnosis of cancers that would not have caused symptoms or death during a person's lifetime.
Uncertainty remains around the magnitude of mortality reduction in current practice. Differences in trial design, screening technology, background treatment quality, adherence, and cause-of-death classification can produce different estimates.
Overdiagnosis is a major source of disagreement. Estimates depend heavily on assumptions about lead time, underlying incidence trends, and whether excess detected cancers would eventually have become clinically important.
There is also uncertainty for people outside the best-studied age ranges or with elevated risk. Personalized screening strategies based on age, breast density, family history, genetics, and prior biopsy findings may change the benefit-harm balance compared with one-size-fits-all screening.
The umbrella claim is actually several claims bundled into one. Each needs its own evaluation.
| Model | Part 1 | Part 2 | Part 3 | Overall |
|---|---|---|---|---|
| Grok 4.3 | No · 72% | No · 58% | No · 45% | No · 90% |
| Mistral Medium 3.5 | No · 72% | No · 58% | No · 45% | No · 90% |
| OpenAI GPT-5.4 | No · 72% | No · 58% | No · 45% | No · 90% |
| Claude Opus 4.7 | No · 72% | No · 58% | No · 45% | No · 90% |
| Gemini 3.1 Pro | — | — | — | Incomplete |
| Llama 4 Maverick | No · 72% | No · 58% | No · 45% | No · 90% |
| Kimi K2.6 | — | — | — | Incomplete |
| GLM 5.1 | No · 72% | No · 58% | No · 45% | No · 90% |
| DeepSeek V4 Pro | No · 72% | No · 58% | No · 45% | No · 90% |
| Qwen 3.7 Max | — | — | — | Incomplete |
The current evidence leans one way. But we're not committed to the conclusion, we're committed to the evidence.
Mammography screening is associated with a reduction in breast cancer mortality of roughly 15-25% relative risk in randomized trials and observational data for women ages 50-74 at average risk, though absolute...
Mammography screening reduces breast cancer-specific mortality for women ages 50 to 74 at average risk, with moderate to high confidence. The U.S. Preventive Services Task Force (USPSTF) and other major guideli...
Mostly yes for breast cancer–specific mortality in women 50–74 at average risk; unclear-to-modest and more value-laden for women 40–49; no good evidence that it reduces all-cause mortality. Confidence: moderate. My independent assessment of the overall claim: Mammography screening can reduce breast cancer mortality, but the effect is modest, depends on age/risk/context, and does not clearly translate into lower all-cause mortality. The strongest support is for average-risk women roughly 50–69 or 50–74 invited to re...
Mammography screening does reduce breast cancer-specific mortality, but the magnitude is modest and the overall benefit-harm balance depends heavily on age, baseline risk, and how overdiagnosis and false positi...
Incomplete response: output limit reached before the answer finished.
Mammography screening likely reduces breast cancer mortality for women aged 50 to 74, but the benefit is less clear for women aged 40 to 49, and there is uncertainty around its impact on all-cause mortality. Fo...
Incomplete response: output limit reached before the answer finished.
Mammography screening reduces breast cancer-specific mortality, particularly for women aged 50 to 74, but it does not reduce all-cause mortality, and the benefit-harm balance for women aged 40 to 49 is not clea...
Mammography screening reduces breast cancer-specific mortality in women aged 50–74 at average risk, but the benefit is smaller and the harm–benefit balance is more contested in women aged 40–49, and there is no...
